# Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT06236139** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 48 (estimated)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Anti-STEAP1 CAR T-cells
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Echocardiography
- **DRUG:** Enzalutamide
- **DRUG:** Fludarabine
- **PROCEDURE:** Leukapheresis
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06236139
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-26
- **Primary completion:** 2027-03-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06236139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06236139, "Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06236139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*